|
Not to my knowledge but the GSK drug is going into Phase II & III clinical trials. It is another targeted therapy for HER2++ women and has shown a 23% response rate and has been granted fast track status by the FDA.
I believe they exclude Herceptin from the early clinical trials to see if the vaccine alone is working. Usually the standards loosen in Phase II or III trials.
Hugs
Christine
|